Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name file name title title
tabling member	label

Search

50483

	registered interest
	date	09/05/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what (a) pharmacological treatments and (b) associated indications the National Institute for Health and Care Excellence has recommended for cancer treatment through either single or multiple technology appraisals in (i) 2012, (ii) 2013 and (iii) 2014.
	tabling member constituency	Manchester, Withington
	tabling member printed	Mr John Leech
	uin	198317
	answer	answer is ministerial correction date of answer 14/05/2014 answer text <p>Information on National Institute for Health and Care Excellence (NICE) technology appraisal recommendations relating to cancer treatments published in 2012, 2013, and 2014, including the estimated size of the eligible patient population and the applicability of the end-of-life flexibilities, is provided in the attached table.</p><p> </p><p>NICE has advised that it publishes a list on its website that includes information on its technology appraisal decisions on cancer treatments. The list, which is updated monthly, includes each appraisal number, year of publication, the appraisal process used, name ofthe technology, the disease or condition for which it has been appraised, the recommendation category and any comments. This information can be found at:</p><p> </p><p>www.nice.org.uk/newsroom/nicestatistics/TADecisions.jsp?domedia=1&amp;mid=CB611E43-19B9-E0B5-D471DEC569F73B12.</p><p> </p><p>NICE does not operate a fixed cost per quality-adjusted life year threshold in its appraisals, but uses a range that allows other factors to be taken into account in deciding whether to recommend a treatment. We are advised that the most likely cost-effectiveness estimate, given as an incremental cost-effectiveness ratio, is published on the NICE website and can be found in the ‘Summary of the Appraisal Committee's key conclusions' table within section four of each appraisal's final technology appraisal guidance documents. The same section of this document also sets out whether a treatment was considered under end-of-life criteria. Further information can be found at:</p><p>www.nice.org.uk</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 198318 198319 198324 198325 question first answered 14/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb attachment 1 file name PQ198317 - NICE Technology Appraisal Recommendations.docx title Technology Appraisal Recommendations
	tabling member	1543 label Biography information for Mr John Leech

50484

	registered interest
	date	09/05/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will publish the determined population size for each pharmacological treatment and associated indications which the National Institute for Health and Care Excellence has (a) recommended for cancer treatment and (b) recommended for cancer treatment under the end-of-life criteria in (i) 2012, (ii) 2013 and (iii) 2014.
	tabling member constituency	Manchester, Withington
	tabling member printed	Mr John Leech
	uin	198325
	answer	answer is ministerial correction date of answer 14/05/2014 answer text <p>Information on National Institute for Health and Care Excellence (NICE) technology appraisal recommendations relating to cancer treatments published in 2012, 2013, and 2014, including the estimated size of the eligible patient population and the applicability of the end-of-life flexibilities, is provided in the attached table.</p><p> </p><p>NICE has advised that it publishes a list on its website that includes information on its technology appraisal decisions on cancer treatments. The list, which is updated monthly, includes each appraisal number, year of publication, the appraisal process used, name ofthe technology, the disease or condition for which it has been appraised, the recommendation category and any comments. This information can be found at:</p><p> </p><p>www.nice.org.uk/newsroom/nicestatistics/TADecisions.jsp?domedia=1&amp;mid=CB611E43-19B9-E0B5-D471DEC569F73B12.</p><p> </p><p>NICE does not operate a fixed cost per quality-adjusted life year threshold in its appraisals, but uses a range that allows other factors to be taken into account in deciding whether to recommend a treatment. We are advised that the most likely cost-effectiveness estimate, given as an incremental cost-effectiveness ratio, is published on the NICE website and can be found in the ‘Summary of the Appraisal Committee's key conclusions' table within section four of each appraisal's final technology appraisal guidance documents. The same section of this document also sets out whether a treatment was considered under end-of-life criteria. Further information can be found at:</p><p>www.nice.org.uk</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 198317 198318 198319 198324 question first answered 14/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb attachment 1 file name PQ198317 - NICE Technology Appraisal Recommendations.docx title Technology Appraisal Recommendations
	tabling member	1543 label Biography information for Mr John Leech

50485

	registered interest
	date	09/05/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will publish the final calculated cost per quality adjusted life year of each pharmacological treatment and associated indications which the National Institute for Health and Care Excellence has recommended for cancer treatments; and which such treatments and indications have been recommended under the end-of-life criteria in (a) 2012, (b) 2013 and (c) 2014.
	tabling member constituency	Manchester, Withington
	tabling member printed	Mr John Leech
	uin	198318
	answer	answer is ministerial correction date of answer 14/05/2014 answer text <p>Information on National Institute for Health and Care Excellence (NICE) technology appraisal recommendations relating to cancer treatments published in 2012, 2013, and 2014, including the estimated size of the eligible patient population and the applicability of the end-of-life flexibilities, is provided in the attached table.</p><p> </p><p>NICE has advised that it publishes a list on its website that includes information on its technology appraisal decisions on cancer treatments. The list, which is updated monthly, includes each appraisal number, year of publication, the appraisal process used, name ofthe technology, the disease or condition for which it has been appraised, the recommendation category and any comments. This information can be found at:</p><p> </p><p>www.nice.org.uk/newsroom/nicestatistics/TADecisions.jsp?domedia=1&amp;mid=CB611E43-19B9-E0B5-D471DEC569F73B12.</p><p> </p><p>NICE does not operate a fixed cost per quality-adjusted life year threshold in its appraisals, but uses a range that allows other factors to be taken into account in deciding whether to recommend a treatment. We are advised that the most likely cost-effectiveness estimate, given as an incremental cost-effectiveness ratio, is published on the NICE website and can be found in the ‘Summary of the Appraisal Committee's key conclusions' table within section four of each appraisal's final technology appraisal guidance documents. The same section of this document also sets out whether a treatment was considered under end-of-life criteria. Further information can be found at:</p><p>www.nice.org.uk</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 198317 198319 198324 198325 question first answered 14/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb attachment 1 file name PQ198317 - NICE Technology Appraisal Recommendations.docx title Technology Appraisal Recommendations
	tabling member	1543 label Biography information for Mr John Leech

50486

	registered interest
	date	09/05/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what (a) pharmacological treatments and (b) associated indications the National Institute for Health and Care Excellence has recommended against in (i) 2012, (ii) 2013 and (iii) 2014.
	tabling member constituency	Manchester, Withington
	tabling member printed	Mr John Leech
	uin	198319
	answer	answer is ministerial correction date of answer 14/05/2014 answer text <p>Information on National Institute for Health and Care Excellence (NICE) technology appraisal recommendations relating to cancer treatments published in 2012, 2013, and 2014, including the estimated size of the eligible patient population and the applicability of the end-of-life flexibilities, is provided in the attached table.</p><p> </p><p>NICE has advised that it publishes a list on its website that includes information on its technology appraisal decisions on cancer treatments. The list, which is updated monthly, includes each appraisal number, year of publication, the appraisal process used, name ofthe technology, the disease or condition for which it has been appraised, the recommendation category and any comments. This information can be found at:</p><p> </p><p>www.nice.org.uk/newsroom/nicestatistics/TADecisions.jsp?domedia=1&amp;mid=CB611E43-19B9-E0B5-D471DEC569F73B12.</p><p> </p><p>NICE does not operate a fixed cost per quality-adjusted life year threshold in its appraisals, but uses a range that allows other factors to be taken into account in deciding whether to recommend a treatment. We are advised that the most likely cost-effectiveness estimate, given as an incremental cost-effectiveness ratio, is published on the NICE website and can be found in the ‘Summary of the Appraisal Committee's key conclusions' table within section four of each appraisal's final technology appraisal guidance documents. The same section of this document also sets out whether a treatment was considered under end-of-life criteria. Further information can be found at:</p><p>www.nice.org.uk</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 198317 198318 198324 198325 question first answered 14/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb attachment 1 file name PQ198317 - NICE Technology Appraisal Recommendations.docx title Technology Appraisal Recommendations
	tabling member	1543 label Biography information for Mr John Leech

50487

	registered interest
	date	09/05/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will publish the final calculated cost per quality adjusted life year of each pharmacological treatment and associated indications which the National Institute for Health and Care Excellence has not recommended for cancer treatment in (a) 2012, (b) 2013 and (c) 2014.
	tabling member constituency	Manchester, Withington
	tabling member printed	Mr John Leech
	uin	198324
	answer	answer is ministerial correction date of answer 14/05/2014 answer text <p>Information on National Institute for Health and Care Excellence (NICE) technology appraisal recommendations relating to cancer treatments published in 2012, 2013, and 2014, including the estimated size of the eligible patient population and the applicability of the end-of-life flexibilities, is provided in the attached table.</p><p> </p><p>NICE has advised that it publishes a list on its website that includes information on its technology appraisal decisions on cancer treatments. The list, which is updated monthly, includes each appraisal number, year of publication, the appraisal process used, name ofthe technology, the disease or condition for which it has been appraised, the recommendation category and any comments. This information can be found at:</p><p> </p><p>www.nice.org.uk/newsroom/nicestatistics/TADecisions.jsp?domedia=1&amp;mid=CB611E43-19B9-E0B5-D471DEC569F73B12.</p><p> </p><p>NICE does not operate a fixed cost per quality-adjusted life year threshold in its appraisals, but uses a range that allows other factors to be taken into account in deciding whether to recommend a treatment. We are advised that the most likely cost-effectiveness estimate, given as an incremental cost-effectiveness ratio, is published on the NICE website and can be found in the ‘Summary of the Appraisal Committee's key conclusions' table within section four of each appraisal's final technology appraisal guidance documents. The same section of this document also sets out whether a treatment was considered under end-of-life criteria. Further information can be found at:</p><p>www.nice.org.uk</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 198317 198318 198319 198325 question first answered 14/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb attachment 1 file name PQ198317 - NICE Technology Appraisal Recommendations.docx title Technology Appraisal Recommendations
	tabling member	1543 label Biography information for Mr John Leech

50445

	registered interest
	date	09/05/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the beneficial effects on patient wellbeing and rate of recovery of hospital beds overlooking green spaces.
	tabling member constituency	Newport West
	tabling member printed	Paul Flynn
	uin	198308
	answer	answer is ministerial correction date of answer 14/05/2014 answer text <p>Healthcare facilities should provide a therapeutic environment in which the overall design of the building contributes to the process of healing. In 2013, the Department published design guidance for acute and mental health hospital inpatient settings acknowledging that views outside, together with access to sunshine or direct daylight, have been shown to benefit a patient's recovery. This might include landscaped gardens or a courtyard with good-quality natural planting. Copies of the guidance, <em>Health Building Note 04-01: Adult in-patient facilities</em> and <em>Health Building Note 03-01: Adult Acute Mental Health Units</em>, have been placed in the Library.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb attachment 1 file name PQ198306_8 - Library Doc - Report - Part 1.pdf title Health Building Note 03-01 2 file name PQ198306_8 - Library Doc - Report - Part 2.pdf title Health Building Note 04-01 grouped question UIN 198306 question first answered 14/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb
	tabling member	545 label Biography information for Paul Flynn

50446

	registered interest
	date	09/05/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what studies his Department has assessed on the treatment of depression and anxiety by increasing access to green spaces in urban areas.
	tabling member constituency	Newport West
	tabling member printed	Paul Flynn
	uin	198306
	answer	answer is ministerial correction date of answer 14/05/2014 answer text <p>Healthcare facilities should provide a therapeutic environment in which the overall design of the building contributes to the process of healing. In 2013, the Department published design guidance for acute and mental health hospital inpatient settings acknowledging that views outside, together with access to sunshine or direct daylight, have been shown to benefit a patient's recovery. This might include landscaped gardens or a courtyard with good-quality natural planting. Copies of the guidance, <em>Health Building Note 04-01: Adult in-patient facilities</em> and <em>Health Building Note 03-01: Adult Acute Mental Health Units</em>, have been placed in the Library.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb attachment 1 file name PQ198306_8 - Library Doc - Report - Part 1.pdf title Health Building Note 03-01 2 file name PQ198306_8 - Library Doc - Report - Part 2.pdf title Health Building Note 04-01 grouped question UIN 198308 question first answered 14/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb
	tabling member	545 label Biography information for Paul Flynn

50398

	registered interest
	date	08/05/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the findings of the recent Global Forum on Incontinence into improving health and social care in incontinence.
	tabling member constituency	Heywood and Middleton
	tabling member printed	Jim Dobbin
	uin	198200
	answer	answer is ministerial correction date of answer 13/05/2014 answer text <p>No assessment has been made of the findings of the recent Global Forum on Incontinence (GFI) into improving health and social care in incontinence. However, we applaud the work of the GFI and the work it is doing to improve the health and social care provisions for incontinence, giving patients and care givers a better quality of life.</p><p> </p><p>Responsibility for continence services sit with NHS England and clinical commissioning groups (CCG). CCGs are responsible for commissioning high quality continence services based on an assessment of local need and performance managing their providers in the delivery of high quality services.</p><p> </p><p>The Mandate to NHS England requires it to deliver continued improvements in relation to enhancing the quality of life for people with long-term conditions, including those suffering incontinence, across the five domains of the NHS Outcomes Framework. NHS England will be taking forward a major programme of work through the Primary Care Strategy; it has established a working group on continence care and will provide an update for the All Party Parliamentary Group for Continence Care on 24 June.</p><p> </p><p>To improve standards in continence care, the Department commissioned the National Institute for Health and Care Excellence (NICE) to develop clinical guidelines on the management of urinary incontinence in women (issued in 2006) and faecal incontinence in adults (issued in 2007), which are supported by commissioning tools to support CCGs. In February, NICE published a clinical Quality Standard on Faecal Incontinence, QS54, which describes high-priority areas for quality improvement in this area. NHS England continues to champion the use of Quality Standards with both commissioners and providers.</p><p> </p><p>We believe all patients have the right to be treated with dignity, respect and compassion.</p><p> </p><p>We recognise that continence can impact on every aspect of peoples' lives and that it often requires a joined approach from both health and social care services. That is why in April the Department published the policy paper, <em>Transforming Primary Care: safe proactive, personalised care for those who need it</em>, which focuses on improving and individualising the management of out of hospital care, directly supporting those with continence problems by creating more integrated health and social care services. This paper has been placed in the Library.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 13/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb attachment 1 file name PQ198200 - Library Doc - Report.pdf title Transforming Primary Care
	tabling member	446 label Biography information for Jim Dobbin

49881

	registered interest
	date	06/05/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, pursuant to the Answer of 27 March 2014, Official Report, column 364W, on mental health services, when the guidance and Choice Framework which he referred to will be published.
	tabling member constituency	Liverpool, Wavertree
	tabling member printed	Luciana Berger
	uin	197978
	answer	answer is ministerial correction date of answer 12/05/2014 answer text <p>The Department published the NHS Choice Framework 2014 on 1 April 2014. A copy has been placed in the Library.</p><p> </p><p>The Department has been working with NHS England and other partners and stakeholders to develop supporting guidance for the National Health Service. A consultation on this will commence shortly and final guidance will be published in the summer.</p><p> </p><p>The Department and NHS England will continue to work with partners and stakeholders to ensure that the extended rights to choice in mental health are fully embedded by 2015 as set out in the NHS Mandate.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb attachment 1 file name PQ197978 - Library Doc - Report.pdf title 2014/15 Choice Framework 2 file name House of Commons Hansard Written Answers for 27 Mar 2014.docx title Mental Health Services Hansard Extract question first answered 12/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb
	tabling member	4036 label Biography information for Luciana Berger

48551

	registered interest
	date	25/04/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what data requirements are necessary to precipitate the development of Clinical Commissioning Group Outcome Indicators based on quality statements 1 and 2 of the NICE quality standard on psoriasis.
	tabling member constituency	Chesham and Amersham
	tabling member printed	Mrs Cheryl Gillan
	uin	196784
	answer	answer is ministerial correction date of answer 06/05/2014 answer text <p>I refer the right hon. Member to the Written Answer I gave her on 9 April 2014, <em>Official Report</em>, column 262-63W.</p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 196785 question first answered 06/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb attachment 1 file name Answer of 9 April - Hansard Extract.docx title Answer of 9 April Hansard Extract column 26263W
	tabling member	18 label Biography information for Dame Cheryl Gillan